Campuses:

virotherapy

Tuesday, May 29, 2018 - 11:10am - 12:00pm
Jana Gevertz (The College of New Jersey)
The heterogeneous nature of cancer observed across different regions of the primary tumor, across metastatic sites, across time, and across patients makes designing efficacious yet tolerable therapies a challenge. Both standard of care and personalized treatment protocols run the risk of not exhibiting a robust anti-tumor response in the face of these uncertainties. Here we introduce a platform for exploring this robustness question.
Subscribe to RSS - virotherapy